A Phase 3 interventional study of Andexanet in Bleeding, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 87 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hemorrhage by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hemorrhage · AstraZeneca.
Among the 12 studies in Hemorrhage by AstraZeneca, this one is one of 2 that started in 2015, is one of 4 in phase 3, and was the 6th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →None of the 12 studies in Hemorrhage by AstraZeneca is open now. The open studies under Hemorrhage, anywhere →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 479 is above the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 131 across the 8 interventional studies, 1,359 across the 4 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Hemorrhage by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute major bleed. The safety of andexanet was also studied.
Key Inclusion Criteria:
Acute major bleeding episode that required urgent reversal of anticoagulation; defined by at least one of the following:
Key Exclusion Criteria:
Participant with an intracerebral hemorrhage that had any of the following:
Participant received any of the following drugs or blood products within 7 days of Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received andexanet as an intravenous bolus administered over \~15 to 30 minutes, followed immediately by a continuous infusion administered over \~120 minutes.
Biological: Andexanet
There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
Also known as: ALXN2070, Andexanet Alfa, PRT064445, Andexxa
Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor
Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100.
Time frame: Baseline, 12 Hours (post infusion)
Participants Achieving Hemostatic Efficacy
Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy.
Time frame: 12 Hours (post infusion)
Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons.
Time frame: Baseline, 12 Hours (post infusion)
| Milestone | Andexanet | Andexanet - Additional Participants |
|---|---|---|
| Started | 477 | 2 |
| Received at least 1 dose of study drug | 477 | 2 |
| Efficacy population | 347 | 2 |
| Death | 3 | 0 |
| Completed | 392 | 2 |
| Not completed | 85 | 0 |
| Withdrew: Death | 78 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 |
Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100.
| Percent Change | FXa Inhibitor: Apixaban | FXa Inhibitor: Rivaroxaban | FXa Inhibitor: Edoxaban | FXa Inhibitor: Enoxaparin | FXa Inhibitor: Rivaroxaban - Additional Participants |
|---|---|---|---|---|---|
| Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor | -93.3 (-94.2 to -92.5) | -94.1 (-95.1 to -93.0) | -71.3 (-82.3 to -65.2) | -75.41 (-79.17 to -66.67) | -96.3 (-98.3 to -94.3) |
Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy.
| Participants | FXa Inhibitor: Apixaban | FXa Inhibitor: Rivaroxaban | FXa Inhibitor: Edoxaban | FXa Inhibitor: Enoxaparin | Bleed Type: Gastrointestinal | Bleed Type: Intracranial Hemorrhage | Bleed Type: Other | Andexanet: Low Dose | Andexanet: High Dose | Overall | FXa Inhibitor: Rivaroxaban - Additional Participants | Bleed Type: Intracranial Hemorrhage - Additional Participants | Andexanet: Low Dose - Additional Participant | Andexanet: High Dose - Additional Participant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Excellent/Good | 134 | 102 | 22 | 14 | 61 | 193 | 18 | 218 | 54 | 272 | 2 | 2 | 1 | 1 |
| Poor/None | 35 | 25 | 6 | 2 | 13 | 51 | 4 | 51 | 17 | 68 | 0 | 0 | 0 | 0 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons.
| Percent Change | FXa Inhibitor: Apixaban | FXa Inhibitor: Rivaroxaban | FXa Inhibitor: Edoxaban | FXa Inhibitor: Enoxaparin | FXa Inhibitor: Rivaroxaban - Additional Participants |
|---|---|---|---|---|---|
| Excellent/Good | -93.4 (-94.3 to -92.6) | -94.6 (-95.2 to -93.5) | -75.8 (-84.4 to -65.2) | -75.20 (-77.08 to -65.91) | -96.3 (-98.3 to -94.3) |
| Poor/None | -93.3 (-95.3 to -90.6) | -92.4 (-96.5 to -85.0) | -65.2 (-85.3 to 3.0) | -78.44 (-82.46 to -74.42) | — |
Collected over Day 1 through Day 37.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andexanet: Low Dose | 66/382 (17.3%) | 157/382 (41.1%) | 40/382 (10.5%) |
| Andexanet: High Dose | 15/97 (15.5%) | 43/97 (44.3%) | 8/97 (8.2%) |
| Event | Andexanet: Low Dose | Andexanet: High Dose |
|---|---|---|
| PneumoniaInfections and infestations | 14/382 | 6/97 |
| Cerebrovascular AccidentNervous system disorders | 4/382 | 4/97 |
| SepsisInfections and infestations | 4/382 | 3/97 |
| Cardiac FailureCardiac disorders | 3/382 | 3/97 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 10/382 | 2/97 |
| Ischaemic StrokeNervous system disorders | 8/382 | 2/97 |
| Cerebral InfarctionNervous system disorders | 3/382 | 2/97 |
| Neurological DecompensationNervous system disorders | 2/382 | 2/97 |
| Acute Myocardial InfarctionCardiac disorders | 3/382 | 2/97 |
| Myocardial InfarctionCardiac disorders | 3/382 | 2/97 |
| Event | Andexanet: Low Dose | Andexanet: High Dose |
|---|---|---|
| Urinary Tract InfectionInfections and infestations | 40/382 | 8/97 |
Safety Population: all participants who received any amount of andexanet.
| Age, Continuous(years) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| Mean | 77.9 ± 10.66 | 71.0 ± 11.31 | 77.9 ± 10.66 |
| Sex: Female, Male(Participants) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| Female | 218 | 1 | 219 |
| Male | 259 | 1 | 260 |
| Ethnicity (NIH/OMB)(Participants) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 0 | 16 |
| Not Hispanic or Latino | 449 | 2 | 451 |
| Unknown or Not Reported | 12 | 0 | 12 |
| Race/Ethnicity, Customized(participants) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| Race : White | 414 | 0 | 414 |
| Race : Black or African American | 29 | 0 | 29 |
| Race : Other | 25 | 2 | 27 |
| Race : Missing | 9 | 0 | 9 |
| Region of Enrollment(participants) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| North America | 212 | 0 | 212 |
| Europe | 248 | 0 | 248 |
| Japan | 17 | 2 | 19 |
| FXa Inhibitor(Participants) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| Apixaban | 245 | 0 | 245 |
| Rivaroxaban | 174 | 2 | 176 |
| Edoxaban | 36 | 0 | 36 |
| Enoxaparin | 22 | 0 | 22 |
| Bleed Type(Participants) | Andexanet | Andexanet - Additional Participants | Total |
|---|---|---|---|
| Gastrointestinal | 109 | 0 | 109 |
| Intracranial Hemorrhage | 329 | 2 | 331 |
| Other | 39 | 0 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Apr 2015 to primary completion in Sep 2020, 65 months.
Results were first posted in Feb 2022, 1 year 4 months after primary completion. A results delay was requested in Sep 2021.
Of 72 phase 3 interventional studies under Hemorrhage, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 65 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRT064445
Alexion Pharmaceuticals, Inc. →